Immunis has developed a novel method to grow human stem cells in clinically compliant conditions, direct them to become highly pure populations of defined immune system
Laguna Beach, CA, USA
One Liner
One Liner
Immunis has developed a novel method to grow human stem cells in clinically compliant conditions, direct them to become highly pure populations of defined immune system
What Problem We are Solving
Problem
Muscle wasting associated with age and immobilization causes a substantial decrease in muscle strength, size and ability of muscle movement. It is caused by a lack of activity, several diseases and in every person as a result of aging (sarcopenia). Most individuals begin to lose muscle mass after the age of thirty, adversely affecting levels of activity and quality of life. The surge in prevalence of chronic diseases and a rise in the geriatric population globally are major factors propelling the muscle wasting disorders market. This sector has attracted several large pharmaceutical companies. The effects of muscle immobilization atrophy in older populations are fast and measurable, resulting in well defined clinical outcome measures
About Us
About Us
We have a solution that prevents muscle atrophy, and reverses it in the aged. The muscle wasting market is $4-7BN, and THERE ARE NO APPROVED DRUGS FOR MUSCLE ATROPHY, with tremendous demonstrable interest by big pharma in this sector
Business Model
Business Model
Complete the current round, providing all necessary funding. Obtain Phase 3 approval in 2 years. Sell or IPO for investor return.
Competitive Advantage
Quote
Ours is the only drug to have been proven to prevent muscular atrophy with age or immobilization, and reverse muscle atrophy caused by age or immobilization. Our drug is very inexpensive to produce, and would be repeatedly taken.
Go-To Market Strategy
Business Strategy
This funding round will allow us to complete Phase 1 and 2 testing, and obtain a Phase 3 award. Over 90% of companies sell when they obtain a Phase 3 award, as our team has personally demonstrated. Thus, we plan to sell within 2-3 years, or IPO.
An FDA-Validated Emerging Sector A Large Market Opportunity Strong Interest by Large Pharmaceutical Companies No current competition in the commercial space
We are open to meeting up to grab a coffee, or just to chat.
We would really enjoy your feedback and insight into our venture and would be happy to discuss anything that you are currently working on to see if we can be of service!
Share
Capital
Name
Amount
Amount Raise To Date
N/A
Investment Type
N/A
Valuation
N/A
Think a friend might be interested in this?
Enter their email to share it with them!
An end-to-end solution to early stage ventures and the firms that support them.
